



F-star Wins “Best Partnership Alliance” Award at the 14th Annual Scrip Awards Ceremony

Cambridge, UK, 29 November 2018 – F-star, a clinical-stage biopharmaceutical company pioneering the development of novel bispecific antibodies that target the immune system to fight cancer, last night won “Best Partnership Alliance” at the Scrip Awards ceremony.

The “Best Partnership Alliance” award recognises F-star’s partnership with Denali Therapeutics – a collaboration announced in August 2016 to discover and develop Fcabs™ (Fc-domains with antigen-binding) for the delivery of medicines into the central nervous system. In May 2018, the partnership resulted in [the early exercise by Denali](#) of its option to acquire the exclusive rights to the programmes and to expand the collaboration. The total consideration amounted to \$24M with further payments of up to \$447M contingent on achieving future milestones.

This award comes at a pivotal period for F-star as it rapidly progresses the next wave of proprietary drugs towards the clinic. Earlier this month, F-star disclosed preclinical data on [two new bispecific programmes](#) that have the potential to deliver a more targeted, potent and safer anti-cancer response while current monospecific approaches (alone or in combination) are showing limitations in the clinic.

Eliot Forster, CEO of F-star, said: *“We are delighted to be recognised amongst many world-class biotech companies at the Scrip Awards. This trophy reflects the hard work of everyone at F-star and the success of our collaborations over the last year. Every day we strive to develop life-changing treatments for cancer patients with our first-in-class biologics and it is gratifying to be recognised amongst peers for the progress we have made.”*

The Scrip Awards were held on 28 November 2018, at the Hilton on Park Lane, London, UK. They recognise the essential role that the biotech, pharmaceutical and other allied industries have played in improving healthcare over the last year. For further details on the awards and other winners, please see: <https://pharmaintelligence.informa.com/events/awards/scrip-awards-2018>

- ENDS-

For further information, please contact:

At F-star

Pierre Peotta

Communications Manager

+44 (0)1223 948 094

For media enquiries

Instinctif Partners

Sue Charles/Ashley Tapp

+44 (0)7392 080 279
pierre.peotta@f-star.com

+44 (0)20 7866 7923
F-star@instinctif.com

About F-star

F-star is a clinical-stage biopharmaceutical company committed to delivering life-changing treatments to those cancer patients who are not well-served by current therapies. Through the development of a deep pipeline of mAb²™ bispecific antibodies, F-star is leading a paradigm shift in immuno-oncology which offers the potential to leapfrog current combination approaches. F-star's disruptive mAb² antibodies deliver a more targeted, efficacious and safer anti-tumour response which is not achievable by combining monotherapies whilst preserving the simplicity and manufacturability of traditional antibodies.

F-star's scientific and clinical expertise has been validated through strategic partnerships with leading pharma and biotech companies.

Find out more at www.f-star.com. Connect with us via [LinkedIn](#) and [Twitter](#)